Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois.
Cancer Research And Biostatistics, Seattle, Washington.
J Thorac Oncol. 2024 Nov;19(11):1564-1577. doi: 10.1016/j.jtho.2024.08.022. Epub 2024 Aug 23.
The International Association for the Study of Lung Cancer developed a global multicenter database to propose evidence-based revisions for the ninth edition of the TNM classification of pleural mesothelioma (PM). This study analyzes the M category to validate eighth edition M category recommendations.
Cases were submitted electronically or by transfer of existing institutional databases for patients with histologically or cytologically confirmed PM. The presence and number of metastases (single versus multiple) in each of eight organ systems were reported for patients with M1 disease at diagnosis. Overall survival (OS) was calculated by the Kaplan-Meier method. Differences in OS were assessed by log-rank test.
Of 7338 submitted cases, 3598 were eligible and 3221 had sufficient data for clinical staging; 228 cases (7%) were M1. Median overall estimated survival was inferior for M1 compared with M0 patients: 10.5 months versus 21.5 months, respectively (p < 0.0001); estimated 1-year survival was 46% versus 71%, respectively. OS differences between M categories were preserved within histologic subgroups. Among 158 patients with organ-specific documentation of M1 disease, there was no statistically significant difference in OS between those with intrathoracic versus more distant metastatic disease (14.4 mo versus 10.9 mo, p = 0.64). No significant survival difference was detected between patients with metastatic disease in a single-organ system versus multiple-organ systems (12.6 mo versus 8.8 mo, p = 0.45).
This evidence-based analysis of the M category for PM conforms with the eighth edition M descriptors. No changes are proposed in the ninth edition of the mesothelioma M category.
国际肺癌研究协会开发了一个全球多中心数据库,旨在为胸膜间皮瘤(PM)的第九版 TNM 分类提出基于证据的修订建议。本研究分析了 M 分期,以验证第八版 M 分期的建议。
通过电子方式或现有机构数据库的转移提交了经组织学或细胞学证实的 PM 患者的病例。报告了诊断为 M1 疾病的患者在 8 个器官系统中每个系统的转移(单发与多发)的存在和数量。通过 Kaplan-Meier 方法计算总生存期(OS)。通过对数秩检验评估 OS 差异。
在提交的 7338 例病例中,有 3598 例符合条件,有 3221 例有足够的临床分期数据;228 例(7%)为 M1。与 M0 患者相比,M1 患者的总估计生存中位数更差:分别为 10.5 个月和 21.5 个月(p<0.0001);估计 1 年生存率分别为 46%和 71%。在组织学亚组中,M 分期之间的 OS 差异得以保留。在 158 例有器官特异性 M1 疾病记录的患者中,胸腔内与更远部位转移疾病的 OS 无统计学差异(14.4 个月对 10.9 个月,p=0.64)。在单个器官系统与多个器官系统转移疾病的患者之间,未检测到生存差异(12.6 个月对 8.8 个月,p=0.45)。
本研究对 PM 的 M 分期进行了基于证据的分析,符合第八版 M 描述符。第九版间皮瘤 M 分期没有提出更改。